Home  /  Resource Library  /  Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Results of a phase I study investigating CAR T therapy Lisocabtagene maraleucel for treatment of relapsed chronic lymphocytic leukemia.